Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease

Author(s): L.M. Schrott , K. Jackson , P. Yi , F. Dietz , G.S. Johnson , T.F. Basting , G. Purdum , T. Tyler , J.D. Rios , T.P. Castor , J.S. Alexander .

Journal Name: Current Alzheimer Research

Volume 12 , Issue 1 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Background: Previous studies showed that Bryostatin-1, a potent PKC modulator and alphasecretase activator, can improve cognition in models of Alzheimer’s disease (AD) with chronic (>10 weeks), intraperitoneal (i.p.) administration of the drug. We compared learning and spatial memory in the APPswe, PSEN1dE985Dbo (APP/PS1) mouse model of AD and studied the ability of acute intraperitoneal and oral Bryostatin-1 to reverse cognitive deficits in this model. Compared to wild-type (WT) mice, APP/PS1 mice showed significant delays in learning the location of a submerged platform in the Morris water maze. Bryostatin-1 was administered over a 2-week course prior to and during water maze testing. Results: Acute i.p. Bryostatin-1 administration did not improve latency to escape but oral Bryostatin-1 significantly improved memory (measured by a reduction in latency to escape). This benefit of oral Bryostatin-1 administration was most apparent during the first 3 days of testing. These findings show that: 1) Bryostatin-1 is orally active in models of learning and memory, 2) this effect can be produced in less than 2 weeks and 3) this effect is not seen with i.p. administration. We conclude that oral Bryostatin-1 represents a novel, potent and long-acting memory enhancer with future clinical applications in the treatment of human AD.

Keywords: Amyloid-beta, aging, bryoids, water maze, memory, hippocampus.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 1
Year: 2015
Page: [22 - 31]
Pages: 10
DOI: 10.2174/1567205012666141218141904

Article Metrics

PDF: 76
HTML: 2